218 related articles for article (PubMed ID: 34853745)
1. An Interesting Case of Euthyroid Graves' Ophthalmopathy, With Negative Thyroid-Stimulating Hormone Receptor Antibodies.
Moeen Z; Aliuddin AM; Gray Wlazlo T; Majid H; Kolli S
Cureus; 2021 Oct; 13(10):e19015. PubMed ID: 34853745
[TBL] [Abstract][Full Text] [Related]
2. Thyroid antibody-negative euthyroid Graves' ophthalmopathy.
Tabasum A; Khan I; Taylor P; Das G; Okosieme OE
Endocrinol Diabetes Metab Case Rep; 2016; 2016():160008. PubMed ID: 27284451
[TBL] [Abstract][Full Text] [Related]
3. Graves' Ophthalmopathy in the Setting of Primary Hypothyroidism.
Alajmi S; Alshehri S; Ekhzaimy A
Cureus; 2022 May; 14(5):e24954. PubMed ID: 35706740
[TBL] [Abstract][Full Text] [Related]
4. Exophthalmos in a young woman with no graves' disease - a case report of IgG4-related orbitopathy.
Erdei A; Steiber Z; Molnar C; Berenyi E; Nagy EV
BMC Ophthalmol; 2018 Jan; 18(1):5. PubMed ID: 29329570
[TBL] [Abstract][Full Text] [Related]
5. Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.
Marinò M; Ionni I; Lanzolla G; Sframeli A; Latrofa F; Rocchi R; Marcocci C
J Endocrinol Invest; 2020 Apr; 43(4):401-411. PubMed ID: 31691261
[TBL] [Abstract][Full Text] [Related]
6. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
Wall JR; Lahooti H
Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
8. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
Wall JR; Lahooti H
Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
[TBL] [Abstract][Full Text] [Related]
9. [Autoantibodies, immunoglobulins and cytokine profile in patients with graves' disease and Graves' orbitopathy].
Sviridenko NY; Bessmertnaya EG; Belovalova IM; Mikheenkov AA; Sheremeta MS; Nikankina LV; Malysheva NM
Probl Endokrinol (Mosk); 2020 Oct; 66(5):15-23. PubMed ID: 33369369
[TBL] [Abstract][Full Text] [Related]
10. Exophthalmos and multinodular goitre, an unusual combination.
Okolie K; Chen D; Ghabrial R; Schmidli R
Endocrinol Diabetes Metab Case Rep; 2019 May; 2019():. PubMed ID: 31051471
[TBL] [Abstract][Full Text] [Related]
11. Thyroid-Stimulating Antibody/Thyroid-Stimulating Hormone Receptor Antibody Ratio as a Sensitive Screening Test for Active Graves' Orbitopathy.
Nakano M; Konishi H; Koshiba M
Endocr Pract; 2022 Oct; 28(10):1050-1054. PubMed ID: 35870804
[TBL] [Abstract][Full Text] [Related]
12. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
[TBL] [Abstract][Full Text] [Related]
13. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.
Gerding MN; van der Meer JW; Broenink M; Bakker O; Wiersinga WM; Prummel MF
Clin Endocrinol (Oxf); 2000 Mar; 52(3):267-71. PubMed ID: 10718823
[TBL] [Abstract][Full Text] [Related]
14. Optimal management of Graves orbitopathy: a multidisciplinary approach.
Soeters MR; van Zeijl CJ; Boelen A; Kloos R; Saeed P; Vriesendorp TM; Mourits MP
Neth J Med; 2011; 69(7):302-8. PubMed ID: 21934174
[TBL] [Abstract][Full Text] [Related]
15. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
16. Correlation of orbital muscle changes evaluated by magnetic resonance imaging and thyroid-stimulating antibody in patients with Graves' ophthalmopathy.
Nishikawa M; Yoshimura M; Toyoda N; Masaki H; Yonemoto T; Gondou A; Kato T; Kurokawa H; Furumura T; Inada M
Acta Endocrinol (Copenh); 1993 Sep; 129(3):213-9. PubMed ID: 8105634
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
18. Modulating gut microbiota in a mouse model of Graves' orbitopathy and its impact on induced disease.
Moshkelgosha S; Verhasselt HL; Masetti G; Covelli D; Biscarini F; Horstmann M; Daser A; Westendorf AM; Jesenek C; Philipp S; Diaz-Cano S; Banga JP; Michael D; Plummer S; Marchesi JR; Eckstein A; Ludgate M; Berchner-Pfannschmidt U;
Microbiome; 2021 Feb; 9(1):45. PubMed ID: 33593429
[TBL] [Abstract][Full Text] [Related]
19. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
Krassas GE; Segni M; Wiersinga WM
Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
[TBL] [Abstract][Full Text] [Related]
20. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
